20.500.12556/DiRROS-27761 Antimeningococcal protection in patients receiving terminal complement inhibitors Introduction: C5 inhibitor (C5i) therapy markedly increases susceptibility to invasive meningococcal disease (IMD) by blocking the terminal complement pathway essential for defense against Neisseria meningitidis. Vaccination is recommended for all recipients, yet breakthrough infections persist. Antibiotic prophylaxis is not universally endorsed, resulting in variable practices. We aimed to assess whether antibiotic prophylaxis provides additional protection beyond vaccination in C5i-treated patients. Methods: The analysis included 124 C5i recipients treated for > 6 months. Patients were classified as receiving single protection (vaccination or antibiotic prophylaxis alone) or combined protection (vaccination and continuous antibiotic prophylaxis). The outcomes were analyzed by prescribed and by implemented regimen; the latter accounting for patient adherence to antibiotic prophylaxis. Results: Of the patients, 60% were prescribed combined protection. Booster vaccination coverage was low (< 40%), and one-quarter of patients did not adhere to antibiotic prophylaxis. The overall incidence of IMD was 0.74 cases per 100 patient-years (PY) (95% confidence interval [CI]: 0.37–1.32). After accounting for noncompliance, the incidence of IMD remained significantly lower in the combined protection group (3.1 [95% CI: 1.5–4.8] vs. 0.5 [95% CI: 0.0–2.7], P = 0.03), corresponding to a 6-fold reduction in risk. Eleven infections were reported, predominantly because of serogroup B (45.5%). Ten patients recovered completely, and 1 had mild residual disability. Conclusion: Although guidelines recommend vaccination alone, our findings indicate that combined protection offers substantially greater protection against IMD in patients receiving long-term C5i. Continued prospective monitoring will be essential to define the optimal preventive strategies in this high-risk population. antibiotic prophylaxis antimeningococcal protection antimeningococcal vaccination atypical hemolytic uremic syndrome complement inhibitors meningococcal infection true false true Angleški jezik Ni določen Neznano 2026-02-24 12:31:01 2026-02-24 12:31:02 2026-02-25 03:50:47 0000-00-00 00:00:00 2026 0 0 Nasl. z nasl. zaslona; Opis vira z dne 5. 1. 2026; str. 1-10 issue 2, [article no.] 103700 Vol. 11 2026 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616 2468-0249 10.1016/j.ekir.2025.11.025 263421955 RAZ_Vujovic_Aleksandra_2026.pdf RAZ_Vujovic_Aleksandra_2026.pdf 1 109502D4AB1280697F60ADD81530DC31 aac18a0e86953e28cac917fbd39a21ab268efad5cdcc4e13df0f0a0ef0a366bc 6e1489e6-1174-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=40800 https://www.kireports.org/article/S2468-0249(25)00710-7/fulltext 0 87885fa8-1174-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=40801 Univerzitetni klinični center Ljubljana 0 0 0